Upperton’s new R&D facility receives MHRA approval

08-Jan-2019 - Last updated on 08-Jan-2019 at 17:02 GMT

(Image: Getty/psisa)

Upperton Pharma’s new and expanded facilities received a positive inspection from MHRA, enabling both research and development and clinical manufacturing at the site.

Upperton Pharma Solutions’ new pharmaceutical manufacturing facilities at Nottingham Science and Technology Park have successfully passed inspection by the UK Medicines and Healthcare products Regulatory Agency (MHRA).

Upperton pharmaceutical, a contract development and manufacturing organization (CDMO), had moved to new facilities in March of 2018. This move to Nottingham from its previous headquarters at BioCity was part of the company’s planned expansion.

The new facilities boost enhancements and expansions of the company’s processing and analytical capabilities.

After the MHRA provided its inspection and deemed the facility as passing, Upperton now has the necessary licenses for manufacture, downstream processing into capsules and tablets, and the release of spray-dried formulations of biotherapeutics and small molecule APIs for use in clinical trials.

Additionally, the company can now develop pharmaceutical formulations for oral, nasal, and pulmonary delivery from early feasibility studies to Phase I and II clinical manufacture.

Richard Johnson, CEO of Upperton Pharma Solutions said in a statement that this endorsement by the MHRA will enable Upperton to have a “seamless transition from [research and development] R&D to [good manufacturing practice] GMP manufacture” which will guarantee that all project-specific information developed in research and development will “flow through to GMP manufacturing processes.”